OYE THEREPEUTICS

Lobbying client · Indiana · filed 2025 to 2026

Pharmaceutical, development stage, company

$100,000 Reported spend

6 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 6 filings. Everything on this page is grouped by the client's LDA id (209650), not by name.

Firms hired 1

BELL & LINDSAY, INC. $100,000 6 filings

Reported by year 2 years

2026 $20,000 2 filings
2025 $80,000 4 filings

Issues lobbied 1

Health Issues 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 9

Defense, Dept of (DOD) 6
Executive Office of the President (EOP) 6
Food & Drug Administration (FDA) 6
Health & Human Services, Dept of (HHS) 6
HOUSE OF REPRESENTATIVES 6
Office of Management & Budget (OMB) 6
Office of Natl Drug Control Policy (NDCP) 6
Office of Science & Technology Policy (OSTP) 6
SENATE 6

Recent filings 6 total

Q2

BELL & LINDSAY, INC.

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $10,000 income · posted Jul 20, 2026

View → Q1

BELL & LINDSAY, INC.

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $10,000 income · posted Apr 20, 2026

View → Q4

BELL & LINDSAY, INC.

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $10,000 income · posted Feb 11, 2026

View → Q3

BELL & LINDSAY, INC.

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $10,000 income · posted Oct 20, 2025

View → Q2

BELL & LINDSAY, INC.

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $30,000 income · posted Jul 21, 2025

View → Q1

BELL & LINDSAY, INC.

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $30,000 income · posted Apr 21, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.